BMS-751324

• UNSPSC Description:

  BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model[1].

• Target Antigen:

  p38 MAPK; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bms-751324.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C(C(NC2CC2)=O)C=C1NC3=NC=NN4C3=C(C)C(C(N(C(OCOC(CC5=CC=C(OP(O)(O)=O)C=C5)=O)=O)CCC)=O)=C4

• Molecular Weight:

  694.63

• References & Citations:

  [1]Liu C, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo [1, 2-f][1, 2, 4] triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases[J]. Journal of medicinal chemistry, 2010, 53(18): 6629-6639.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  948842-66-8